- Topic
257k Popularity
4k Popularity
3k Popularity
22k Popularity
17k Popularity
- Pin
- Gate July 2025 Transparency Report:
Accelerating Leadership in the Global Crypto Landscape!
#GateTransparencyReport# - 📢 Gate Square Exclusive: #PUBLIC Creative Contest# Is Now Live!
Join Gate Launchpool Round 297 — PublicAI (PUBLIC) and share your post on Gate Square for a chance to win from a 4,000 $PUBLIC prize pool
🎨 Event Period
Aug 18, 2025, 10:00 – Aug 22, 2025, 16:00 (UTC)
📌 How to Participate
Post original content on Gate Square related to PublicAI (PUBLIC) or the ongoing Launchpool event
Content must be at least 100 words (analysis, tutorials, creative graphics, reviews, etc.)
Add hashtag: #PUBLIC Creative Contest#
Include screenshots of your Launchpool participation (e.g., staking record, reward - 🎉 Hey Gate Square friends! Non-stop perks and endless excitement—our hottest posting reward events are ongoing now! The more you post, the more you win. Don’t miss your exclusive goodies! 🚀
🆘 #Gate 2025 Semi-Year Community Gala# | Square Content Creator TOP 10
Only 1 day left! Your favorite creator is one vote away from TOP 10. Interact on Square to earn Votes—boost them and enter the prize draw. Prizes: iPhone 16 Pro Max, Golden Bull sculpture, Futures Vouchers!
Details 👉 https://www.gate.com/activities/community-vote
1️⃣ #Show My Alpha Points# | Share your Alpha points & gains
Post your
The identification of the executive director of Linghang Medical Biotechnology is exposed: Two founders of Conflux hold concurrent positions.
According to Gate News bot, the latest public information shows that Long Fan and Wu Ming, the two founders of Conflux, also serve as executive directors of the Hong Kong-listed company Leading Pharmaceutical Biotechnology.
Navi Pharmaceutical Biotechnology currently has a total market value of approximately HKD 371 million (equivalent to USD 47.26 million). Meanwhile, the total market value of Conflux (CFX) token has reached USD 393 million, ranking 138th in the cryptocurrency market capitalization leaderboard.
Earlier reports indicated that Pioneer Pharma Biotechnology (00399) announced that the company will sign a memorandum of understanding with Northwestern Foundation (the seller) and Conflux on June 30, 2025, with the intention of acquiring all the shares of the target company. This potential acquisition aims to assist the company in entering the digital innovation field, which will not only diversify the group’s business but is also expected to bring new profit growth points for the group.